Pfizer Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pfizer (PFE).

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

7Buy

10Hold

2Sell

Consensus RatingNeutral# Analysts19Avg. Consensus PT$30Upside to Avg. PT+8.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$30→$33
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$28→$30
Aug 7, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$35→$31
Jul 13, 2026	BMO Capital	Evan David Seigerman	PT Cut	Outperform	$34→$30
Jul 13, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$36→$35
Jul 10, 2026	B of A Securities	Jason Gerberry	PT Cut	Neutral	$27→$26
Jul 8, 2026	JP Morgan	Chris Schott	PT Cut	Neutral	$30→$28
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Neutral	$27
Jul 6, 2026	HSBC	Rajesh Kumar	Downgrade	Buy→Hold	$32→$28
Jun 10, 2026	RBC Capital	Trung Huynh	Upgrade	Underperform→Sector Perform	$25
Apr 29, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$26→$27
Apr 20, 2026	RBC Capital	Trung Huynh	Maintained	Underperform	$25
Apr 16, 2026	CICC	Jin Zhang	Initiate	Outperform	$33
Apr 13, 2026	UBS	Michael Yee	PT Raise	Neutral	$25→$27
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$27→$28
Apr 9, 2026	B of A Securities	Jason Gerberry	PT Cut	Neutral	$27→$26
Mar 24, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$35→$36
Mar 17, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$29→$32
Mar 2, 2026	Argus Research	David Toung	Upgrade	Hold→Buy	$35
Feb 25, 2026	RBC Capital	Trung Huynh	Initiate	Underperform	$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Maintains Hold on Pfizer, Raises Price Target to $30

HSBC analyst Rajesh Kumar maintains Pfizer (NYSE:PFE) with a Hold and raises the price target from $28 to $30.

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.

Avi Kapoor

PRO
Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $35 to $31.

Benzinga Newsdesk

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.

Avi Kapoor

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.

Vandana Singh

Pfizer Inc

Pfizer Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HSBC Maintains Hold on Pfizer, Raises Price Target to $30

PRO
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

PRO
Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

People Also Watch

People Also Watch

Pfizer Inc

Pfizer Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHSBC Maintains Hold on Pfizer, Raises Price Target to $30

PROCNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

PROGuggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

People Also Watch

People Also Watch

PRO
HSBC Maintains Hold on Pfizer, Raises Price Target to $30

PRO
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy

PRO
Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31